



M&A Activity

- 2023's M&A environment has witnessed modest pullback from Q1 2023's peak activity with month-over-month declines during the spring and early summer, though activity remains relatively strong when compared to 2022. Forecasts for the remainder of 2023 suggest cautious optimism despite pressures from equity markets, geopolitical tensions, and questions around interest rates. The United States remains an attractive market with strong consumer spending, low unemployment, and recent GDP growth of 4.9% providing an economic boost. Corporate and private equity buyers are likely to continue their search for deals to deploy their war chests and are expected to continue to target digital transformation and distressed opportunities across North America and Europe.
- On September 25, 2023, Regeneron Pharmaceuticals, Inc. announced that it successfully completed its \$209 million acquisition of Decibel Therapeutics, Inc. The acquisition of Decibel builds on prior collaboration between the companies and includes three ongoing gene therapy programs targeting different forms of congenital, monogenic hearing loss.
- On September 20, 2023, Alexion, AstraZeneca Rare Disease, completed a definitive purchase and license agreement for a portfolio of preclinical rare disease gene therapy programs and enabling technologies from Pfizer Inc. for approximately \$1.0 billion. These new resources build on the combined capabilities of Alexion and AstraZeneca in genomic medicine.
- On August 30, 2023, Novo Nordisk acquired Embark Biotech and its lead asset targeting obesity and other cardiometabolic diseases for approximately \$515 million. The two companies have also entered a three-year research and development collaboration for discovering and developing new therapeutics for obesity and treatment for its related co-morbidities.
- On August 10, 2023, Novo Nordisk announced that it agreed to acquire Inversago for up to \$1.075 billion in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.


Trend in Industry Revenue Multiples¹



Trends in Revenue Growth¹




Relative Stock Price Returns²



¹ Calculated using aggregated data for AMGN, GILD, BIIB, CSL Limited, CELG, VRTX, REGN, ALXN, BMRN, INCY, ABBV, NOVO B, SGEN, IONS, ALNY, SRPT, BLUE, BGNE, MRNA, NBIX.

² Biotechnology is a custom, equal-weighted index constructed with the aforementioned companies.

Purchase Price Allocation (PPA) % from Recent Transactions



Notable M&A Deals

On October 6, 2023, Amgen announced that it completed its acquisition of Horizon Therapeutics plc for \$116.50 per share in cash, representing a transaction equity value of approximately \$27.8 billion. Horizon Therapeutics focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.

On September 26, 2023, Biogen Inc. completed the \$7.7 billion acquisition of Reata Pharmaceuticals, Inc., a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS®, as well as other clinical and preclinical pipeline programs.

